quiet here, page-5

had a brief read through the full year report. Doesn't appear to be too much of note there (that isn't already known)

Anyone else see anything worth noting?



- Ramp up of UK stem cell operations "aggressive marketing"... "it is envisaged that international sales, especially in the UK, will grow rapidly in FY 2013"

- cash and cash equivalents of $578k at 30th of Jun12.

- review date of bank facility 31st Dec-12.

- "Management has prepared a cash flow forecast for the 12 months ending September 2013 that supports the ability of the entity to continue as a going concern. The cash flow forecast assumes a 4% increased in sales, the extension of the bank loan facility, the extension of Pacific Devices loan and a new $1 million debt facility. The Directors are presently satisfied that the cash flow forecast will be achieved."

4% increased in sales would take them to just shy of 10million, seems reasonable. IMO I'd hope they set their sights slightly higher and manage something around the 11million mark, combined with better cost control which might see them trim their loss and avoid further dilution.